TNNI3 and amyloidosis: At present, the most accepted system for estimating survival in patients with amyloidosis and cardiac involvement is the 2012 Mayo stage, which is based on cardiac troponin I (cTnI), N-terminal natriuretic peptide type B (NT-proBNP) and difference between involved and uninvolved free light chain (dFLC) levels (7).